Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 5/20 | 0.44 |
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.39 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4070469 | 1.00 | KDM4C (0.51) | KDM4CL3MBTL1CA2CA1NPC1 | |
| SCHEMBL4074819 | 0.92 | KDM4C (0.46) | KDM4CL3MBTL1CA2CA1NPC1 | |
| SCHEMBL4074827 | 0.92 | KDM4C (0.46) | KDM4CL3MBTL1CA2CA1NPC1 | |
| SCHEMBL7852875 | 0.86 | CA2 (0.45) | KDM4CCA2CA1CA12CA9 | |
| SCHEMBL29865973 | 0.86 | CA2 (0.45) | KDM4CCA2CA1CA12CA9 | |
| SCHEMBL5422297 | 0.84 | KDM4C (0.51) | KDM4CL3MBTL1CA2CA1NPC1 | |
| SCHEMBL10686057 | 0.84 | KDM4C (0.51) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL14065688 | 0.84 | KDM4C (0.51) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL13953759 | 0.84 | KDM4C (0.51) | KDM4CL3MBTL1CA2CA1NPC1 | |
| SCHEMBL4078714 | 0.83 | KDM4C (0.49) | KDM4CL3MBTL1CA2CA1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365192-B2 | Pyridine compound substituted with azole | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-21 | — | — | US | disclosed |
| EP-3559011-B1 | ANTIVIRAL ESTER PRODRUGS OF TENOFOVIR | MERCK SHARP & DOHME (US) | 2022-04-13 | — | — | EP | disclosed |
| EP-3559011-B1 | ANTIVIRAL ESTER PRODRUGS OF TENOFOVIR | MERCK SHARP & DOHME (US) | 2022-04-13 | — | — | EP | disclosed |
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2021-04-29 | — | — | US | disclosed |
| EP-3666766-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | Taisho Pharmaceutical Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| CN-110914254-A | Azole-substituted pyridine compound | 大正制药株式会社 | 2020-03-24 | — | — | CN | disclosed |
| US-10519159-B2 | Antiviral aliphatic ester prodrugs of tenofovir | MERCK SHARP & DOHME CORP. (US) | 2019-12-31 | — | — | US | disclosed |
| EP-3559011-A1 | ANTIVIRAL ALIPHATIC ESTER PRODRUGS OF TENOFOVIR | Merck Sharp & Dohme Corp. (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20180179208-A1 | ANTIVIRAL ALIPHATIC ESTER PRODRUGS OF TENOFOVIR | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | US | disclosed |
| US-20180179208-A1 | ANTIVIRAL ALIPHATIC ESTER PRODRUGS OF TENOFOVIR | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | US | disclosed |
| WO-2006066914-A2 | CARBAMATE SUBSTITUTED IMIDAZO- AND PYRROLO-PYRIDINES AS PROTEIN KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006066913-A2 | BENZAMIDE SUBSTITUTED IMIDAZO- AND PYROLO-PYRIDINES AS PROTEIN KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | disclosed |
| EP-1307447-B1 | 3-INDOLYL-4-PHENYL-1H-PYRROLE-2,5-DIONE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3BETA | HOFFMANN LA ROCHE (CH) | 2004-12-15 | — | — | EP | disclosed |
| US-20040110742-A1 | Dihydrodiaryloxazepine derivative and pharmaceutical composition containing the same | AJINOMOTO CO., INC. (JP) | 2004-06-10 | — | — | US | disclosed |
| EP-1403258-A1 | DIHYDRODIARYLOXAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2004-03-31 | — | — | EP | disclosed |
| EP-1307447-A2 | 3-INDOLYL-4-PHENYL-1H-PYRROLE-2,5-DIONE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-07 | — | — | EP | disclosed |
| US-20020188018-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | GONG LEYI (US) | 2002-12-12 | — | — | US | disclosed |
| US-6479490-B2 | TREATMENT OF DISEASES CHARACTERIZED BY EXCESS TH2 CYTOKINES AND/ OR AN EXCESS IGE PRODUCTION. | SYNTEX (U.S.A.) LLC | 2002-11-12 | — | — | US | disclosed |
| US-20020052397-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | SYNTEX (U.S.A.) LLC | 2002-05-02 | — | — | US | disclosed |
| WO-2002010158-A2 | 3-INDOLYL-4-PHENYL-1H-PYRROLE-2,5-DIONE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | CYP2C19, CYP4A11, CYP11B1 | KDM4C 480/4885L3MBTL1 4871/4885CA2 363/4885 |
| US-10519159-B2 | Antiviral aliphatic ester prodrugs of tenofovir | TYMP, PNP, GART | KDM4C 2007/4885L3MBTL1 2281/4885CA2 4183/4885 |
| US-11365192-B2 | Pyridine compound substituted with azole | CYP2C19, CYP4A11, CYP11B1 | KDM4C 480/4885L3MBTL1 4871/4885CA2 363/4885 |
| US-20040110742-A1 | Dihydrodiaryloxazepine derivative and pharmaceutical composition containing the same | CYP3A4, PPARD, CYP4B1 | KDM4C 1121/4885L3MBTL1 4810/4885CA2 2657/4885 |
| US-20020052397-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | GSK3B, GSK3A, PYGL | KDM4C 2961/4885L3MBTL1 4570/4885CA2 1632/4885 |
| US-20020188018-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | GSK3B, GSK3A, PYGL | KDM4C 1889/4885L3MBTL1 4448/4885CA2 1338/4885 |
| US-20180179208-A1 | ANTIVIRAL ALIPHATIC ESTER PRODRUGS OF TENOFOVIR | TYMP, PNP, GART | KDM4C 1992/4885L3MBTL1 2305/4885CA2 4235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.